Low-dose oral mini-pulse dexamethasone therapy in progressive unstable vitiligo

Journal of Cutaneous Medicine and Surgery

Volumn 17, Issue 4, 2013, Pages 259-268

  Kanwar, Amrinder J ^a   Mahajan, Rahul ^a   Parsad, Davinder ^a  

^a POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

Author keywords

[No Author keywords available]

Indexed keywords

DEXAMETHASONE;

ACNE; ADOLESCENT; ADULT; ARTHRALGIA; ARTICLE; BODY SURFACE; CHILD; DISEASE ACTIVITY; DISEASE FREE SURVIVAL; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG PULSE THERAPY; DRUG WITHDRAWAL; FAMILY HISTORY; FEMALE; FOLLOW UP; HUMAN; LETHARGY; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; ONSET AGE; PRESCHOOL CHILD; PRIORITY JOURNAL; RELAPSE; RETROSPECTIVE STUDY; SCHOOL CHILD; SIDE EFFECT; SKIN PIGMENTATION; STOMACH DISEASE; VITILIGO; WEAKNESS; WEIGHT GAIN;

ADMINISTRATION, ORAL; ADOLESCENT; DEXAMETHASONE; DISEASE PROGRESSION; FEMALE; GLUCOCORTICOIDS; HUMANS; MALE; PULSE THERAPY, DRUG; RETROSPECTIVE STUDIES; VITILIGO;

EID: 84883196732     PISSN: 12034754     EISSN: None     Source Type: Journal    
DOI: 10.2310/7750.2013.12053     Document Type: Article

References (21)

1. Taï eb A, Picardo M. Therapy of vitiligo: management overview. In: Picardo M, Taï eb A, editors. Vitiligo. 1st ed. New York: Springer; 2010. p. 319-24.
2. Pasricha JS, Khaitan BK. Oral mini-pulse therapy with betamethasone in vitiligo patients having extensive or fast-spreading disease. Int J Dermatol 1993;32:753-7, doi:10.1111/j.1365-4362.1993. tb02754.x.
3. Alikhan A, Felsten LM, Daly M, Petronic-Rosic V. Vitiligo: a comprehensive overview-part I. Introduction, epidemiology, quality of life, diagnosis, differential diagnosis, associations, histopathology, etiology, and work-up. J Am Acad Dermatol 2011;65:473-91, doi:10.1016/j.jaad.2010.11.061.
4. Liu JB, Li M, Yang S, et al. Clinical profiles of vitiligo in China: an analysis of 3742 patients. Clin Exp Dermatol 2005;30:327-31, doi:10.1111/j.1365-2230.2005.01813.x.
5. Moellmann G, Klein-Angerer S, Scollay DA, et al. Extracellular granular material and degeneration of keratinocytes in the normally pigmented epidermis of patients with vitiligo. J Invest Dermatol 1982;79:321-30, doi:10.1111/1523-1747.ep12500086.
6. Cui J, Arita Y, Bystryn JC. Cytolytic antibodies to melanocytes in vitiligo. J Invest Dermatol 1993;100:812-5, doi:10.1111/1523- 1747.ep12476636.
7. Falabella R, Arrunategui A, Barona MI, Alzate A. The minigrafting test for vitiligo: detection of stable lesions for melanocyte transplantation. J Am Acad Dermatol 1995;32:228-32, doi:10. 1016/0190-9622(95)90131-0.
8. Picardo M, Taieb A. Pathophysiology overview. In: Picardo M, Taieb A, editors. Vitiligo. 1st ed. New York: Springer; 2010. p. 149-52.
9. Hann SK, Kim HI, Im S, et al. The change of melanocyte cytotoxicity after systemic steroid treatment in vitiligo patients. J Dermatol Sci 1993;6:201-5, doi:10.1016/0923-1811(93)90039-R.
10. Hann SK, Chen D, Bystryn JC. Systemic steroids suppress antimelanocyte antibodies in vitiligo. J CutanMed Surg 1997;1:193-5.
11. Farah FS, Kurban AK, Chaglassian HT. The treatment of vitiligo with oral psoralens and triamcinolone by mouth. Br J Dermatol 1967;79:89-91, doi:10.1111/j.1365-2133.1967.tb11461.x.
12. Kandil E. Treatment of localized vitiligo with intradermal injections of triamcinolone acetonide. Dermatologica 1970;140: 195-206, doi:10.1159/000252552.
13. Gokhale BB, Gokhale TB. Corticotrophin and vitiligo (preliminary observation). Br J Dermatol 1976;98:578-9.
14. Imamura S, Tagami H. Treatment of vitiligo with oral corticosteroids. Dermatologica 1976;153:179-85, doi:10.1159/000251114.
15. Kim SM, Lee HS, Hann SK. The efficacy of low-dose oral corticosteroids in the treatment of vitiligo patients. Int J Dermatol 1999;38:546-50, doi:10.1046/j.1365-4362.1999.00623.x.
16. Pasricha JS, Seetharam KA, Dashore A. Evaluation of five different regimes for the treatment of vitiligo. Indian J Dermatol Venereol Leprol 1989;55:18-21.
17. Radakovic-Fijan S, Fürnsinn-Friedl AM, Ho?nigsmann H, Tanew A. Oral dexamethasone pulse for vitiligo. J Am Acad Dermatol 2001; 44:814-7, doi:10.1067/mjd.2001.113475.
18. Kanwar AJ, Dhar S, Dawn G. Oral minipulse therapy in vitiligo. Dermatology 1995;190:251-2, doi:10.1159/000246705.
19. Seiter S, Ugurel S, Tilgen W, Reinhold U. Use of intravenous methyl prednisolone pulse therapy in progressive vitiligo. Int J Dermatol 2000;39:624-7, doi:10.1046/j.1365-4362.2000.00006.x.
20. Namita R, Kar HK, Sunil S. An open labeled, comparative clinical study on efficacy and tolerability of oral minipulse of steroid (OMP) alone, OMP with PUVA and broad/narrow band UVB phototherapy in progressive vitiligo. Indian J Dermatol Venereol Leprol 2008;74:357-60, doi:10.4103/0378-6323.42905.
21. Majid I, Masood Q, Hassan I, et al. Childhood vitiligo: response to methylprednisolone oral minipulse therapy and topical fluticasone combination. Indian J Dermatol 2009;54:124-7, doi:10.4103/0019- 5154.53185.